EDEX (alprostadil) by R-Pharm US is prostaglandin receptor agonists [moa]. First approved in 1997.
Drug data last refreshed 2h ago · AI intelligence enriched 6d ago
EDEX (alprostadil) is a prostaglandin receptor agonist administered by injection for erectile dysfunction. It works by dilating blood vessels and relaxing smooth muscle to increase penile blood flow. This small-molecule therapeutic addresses a well-established patient need in sexual medicine.
Moderate competitive pressure (30/100) and approaching loss of exclusivity signal a contracting team with focus on market defense and cost management rather than expansion.
Prostaglandin Receptor Agonists
Prostaglandin Analog
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Learn About the Study Medicine - Precedex in Children From Japan.
Precedex Special Investigation (in Pediatric Patients)
Study of OZURDEX® in the Treatment of Diabetic Macular Oedema (DME) in Australia - The AUSSIEDEX Study
Study to Evaluate Hemodynamic Effect of Different Loading Doses of Precedex in Post-surgical Intensive Care Unit (ICU) Patients
Cerebral Perfusion Pressure Using Precedex and Other Sedatives
Worked on EDEX at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on EDEX offers exposure to sexual medicine marketing and specialty/urology channels but in a declining product lifecycle. Career growth will be constrained; opportunities lie in managed care negotiation and defending market share rather than driving expansion.